- Expression of miRNA 146a/b, 221 and 222 in Thyroid Cancer.
-
Young Suk Jo, Ihn Suk Lee, Woojeong Hong, In Sang Song, Minho Shong, Je Ryoung Kim
-
J Korean Endocr Soc. 2009;24(1):17-24. Published online March 1, 2009
-
DOI: https://doi.org/10.3803/jkes.2009.24.1.17
-
-
1,674
View
-
22
Download
-
1
Crossref
-
 Abstract
 PDF
- BACKGROUND
miRNAs can be diagnostic markers and therapeutic targets in cancers, but few studies have been conducted in thyroid cancer. We investigated the expression levels of miRNA 146a/b, 221, and 222 which are important miRNAs in papillary thyroid cancers (PTCa), and verified their impact on clinicopathological factors. METHODS: We measured the expression of pre-miRNAs 146a/b, 221, and 222 in NPA cells treated with 10% fetal bovine serum (FBS) or in HEK293T cells transfected with RET/PTC3 or BRAFV600E expression vectors. We also investigated the relationship between miRNA expression levels in thyroid cancer tissue specimens and clinicopathological parameters. RESULTS: Growth stimulation with 10% FBS induced miRNA expressions in NPA cells, and transfection of RET/PTC3 and BRAFV600E also increased the expression of these miRNAs in HEK293T cells. Most (25 cases; 50%) of PTCa showed increased expression of miRNA-146a/b and 30 cases (60%) had elevated expression of miRNA-221 and miRNA-222 compared to normal thyroid samples from the contralateral lobe. However, increased miRNA expression did not correlate with clinicopathological factors. CONCLUSION: Expression of miRNA 146a/b, 221, and 222 was increased by BRAFV600E and RET/PTC3 rearrangement and might have a role in tumorigenesis in PTCa. However, expression levels of these miRNAs did not correlate with clinicopathological parameters of patients with PTCa.
-
Citations
Citations to this article as recorded by  - Expression of miRNA 146a/b, 221 and 222 in Thyroid Cancer
Do Joon Park
Journal of Korean Endocrine Society.2009; 24(1): 15. CrossRef
|
KES
